GSK actions to support global response to COVID-19 including a $10 million donation to the WHO Solidarity Response Fund
GSK is closely monitoring the COVID-19 pandemic and is supporting global efforts to tackle the virus. Since the outbreak, GSK has been actively exploring ways to help, with their science and expertise, alongside protecting the health and wellbeing of their people and managing global supply chains to support patients and consumers who depend on their products.
GSK has provided the following update on the actions they are taking to support the global response to COVID-19.
• GSK is donating $10 million to WHO and the UN Foundation’s COVID-19 Solidarity Response Fund to support WHO and partners prevent, detect, and manage the pandemic, particularly where the needs are the greatest.
• Expansion of their vaccines collaborations – they are now working with five partner companies and research groups across the world, including in the USA and China. This builds on their previous announcements regarding partnerships with the University of Queensland and Clover Biopharmaceuticals to make their vaccine adjuvant technology available to support their respective COVID-19 vaccine research programs. The use of an adjuvant is of particular importance in a pandemic situation since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and therefore contributing to protection of more people.
• GSK is entering a new collaborative research effort, the COVID-19 Therapeutics Accelerator, by making available compounds from their libraries for screening, with the aim of bringing forward the most promising molecules that could be used to treat cases of COVID-19.
• GSK is also evaluating their marketed medicines and those in development, to determine if any could be used beyond their current indications, and evaluating options to make available their specialised laboratory space to help in research and testing of COVID-19.
• GSK is also donating surplus reagents to countries to support diagnostic testing, preparing to do the same for surplus personal protective equipment (PPE) and have initiated a volunteering processes for employees, to enable those with medical expertise to provide support to frontline health workers.
• GSK Consumer Healthcare is prioritizing actions in its supply chain to deliver more consumer products that are in high demand, due to COVID-19. This includes increasing production for pain relief brands such as Panadol and multi-vitamins and dietary supplements such as Emergen-C and Centrum.
GSK continues to monitor the situation closely and take actions to develop their response to the pandemic. In doing so, GSK will continue to put the needs of patients and their people first at all times.
For a complete overview of GSK’s efforts regarding this outbreak, please see their website.